Nintedanib Clonmel Healthcare (Nintedanib)

• Nintedanib is indicated for fibrotic lung diseases and as part of combination regimens in certain cancers.
• Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression in affected patients.
• Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity and delays worsening of respiratory symptoms.
• Non‑small cell lung cancer (in combination therapy): enhances overall treatment efficacy when used with standard chemotherapy agents.
• Progressive fibrosing interstitial lung disease: offers therapeutic benefit across various fibrotic lung conditions beyond IPF.
• Idiopathic pulmonary fibrosis (severe): may reduce acute exacerbations.

• Nintedanib inhibits multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR 1‑3), platelet‑derived growth factor receptors (PDGFR α/β) and fibroblast growth factor receptors (FGFR 1‑3). By blocking these pathways, it reduces endothelial cell proliferation, fibroblast activation, and extracellular matrix deposition, thereby attenuating angiogenesis and fibrotic remodeling in lung tissue and tumor micro‑environments. The inhibition is dose‑dependent and leads to decreased signaling that drives pathological tissue scarring.

Nintedanib may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Diarrhea: frequent loose stools that may be mild to moderate.
• Nausea: feeling of sickness often accompanied by loss of appetite.
• Vomiting: occasional episodes, usually less severe than diarrhea.
• Elevated liver enzymes: mild increases in ALT/AST observed in monitoring.

Serious or Rare Side Effects

• Hepatic injury: rare cases of severe liver damage requiring discontinuation.
• Bleeding events: increased risk of gastrointestinal or other bleeding, especially with anticoagulants.
• Cardiovascular events: rare occurrences of arterial thromboembolism or hypertension.

• When prescribing Nintedanib, clinicians should consider several precautionary measures to ensure patient safety.
• Renal function: assess baseline kidney function and monitor periodically in patients with impairment.
• Hepatic function: perform liver enzyme tests before initiation and regularly during therapy.
• Bleeding risk: evaluate concomitant use of anticoagulants or antiplatelet agents and adjust as needed.
• Pregnancy and lactation: use only if potential benefits justify potential risks, as data are limited.
• Drug interactions: review all concomitant medications for CYP3A4 substrates or inhibitors.
• Store at ambient temperature: keep capsules in the original container, protect from moisture and heat.

Nintedanib interacts with several medicines; awareness of these interactions helps to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nintedanib plasma concentrations and increase toxicity.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of bleeding when combined.
• P‑glycoprotein inhibitors (e.g., verapamil): can elevate drug exposure and adverse effects.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower nintedanib levels and reduce therapeutic benefit.
• Antacids containing aluminum or magnesium: may impair absorption if taken simultaneously; separate dosing by at least 2 hours.
• Diuretics: monitor for dehydration and renal function changes during combined use.